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Abstract: Hyponatremia is an electrolyte disorder frequently observed in several clinical 
settings and common in hospitalized patients with decompensated heart failure (HF). It is 
caused by deregulation of arginine vasopressin (AVP) homeostasis associated with water 
retention in hypervolemic or in euvolemic states. While hypervolemic hypotonic hypona-
tremia is also seen in advanced liver cirrhosis, renal failure, and nephrotic syndrome, the 
bulk of evidence associating this electrolyte disorder to increasing morbidity and mortal-
ity can be found in the HF literature. Hospitalized HF patients with low serum sodium 
concentration have lower short-term and long-term survival, longer hospital stay and 
increased readmission rates. Conventional therapeutic approaches, ie, restriction of fluid 
intake, saline and diuretics, can be effective, but often the results are unpredictable. Recent 
clinical trials have demonstrated the effectiveness of nonpeptide AVP receptor antagonists 
(vaptans) in the treatment of hyponatremia. The vaptans induce aquaresis, an electrolyte-spar-
ing excretion of free water resulting in the correction of serum sodium concentrations and 
plasma osmolality, without activation of the renin-angiotensin-aldosterone system (RAAS) 
or changes in renal function and blood pressure. Further prospective studies in a selected 
congestive HF population with hyponatremia, using clinical-status titrated dose of tolvaptan, 
are needed to determine whether serum sodium normalization will be translated into a better 
long-term prognosis. This review will focus on recent clinical trials with tolvaptan, an oral V2 
receptor antagonist, in HF patients. The ability of tolvaptan to safely increase serum sodium 
concentration without activating the RAAS or compromising renal function and electrolyte 
balance makes it an attractive agent for treating hyponatremic HF patients.
Keywords: hyponatremia, heart failure, AVP receptor antagonists, tolvaptan, serum 
sodium
Introduction
Sodium homeostasis is vital to the normal physiologic function of the cells. Sodium 
concentration is regulated by stimulation of thirst, secretion of antidiuretic hormone 
(ADH), feedback mechanisms of the renin-angiotensin-aldosterone system (RAAS), 
and variations in renal handling of filtered sodium.
Hyponatremia is defined as serum sodium level of 135 mEq/L and is considered 
severe when the serum sodium level is 125 mEq/L. It is an important and common 
electrolyte abnormality that can be seen in isolation or, as most often is the case, as 
a complication of other medical illnesses associated with hypervolemia such as heart 
failure (HF), liver cirrhosis and the syndrome of inappropriate antidiuretic hormone 
secretion (SIADH).1International Journal of Nephrology and Renovascular Disease 2010:3 52
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The clinical manifestations depend on the severity and 
duration of hyponatremia and rapidity of decrease in sodium 
levels. Signs and symptoms of acute (48 hours) severe 
hyponatremia are primarily related to the central nervous 
system as the osmotic pressure gradient promotes water 
movement into brain cells, resulting in life-threatening 
cerebral edema and encephalopathy.2 Patients with chronic 
hyponatremia or a serum sodium level from 125 to 134 mmol/L 
may be asymptomatic or have less severe symptoms (fatigue, 
nausea, vomiting, and anorexia).
However in spite of a less serious clinical manifestations, 
hyponatremia is a predictor of poor outcomes in patients 
with HF, and the pathogenesis of this disorder reflects the 
underlying severity of HF, as well as attempts to manage 
fluid overload.3 This review will focus on hyponatremia in 
HF setting and the role of the V2 receptor antagonist tolvaptan 
in its management.
Hyponatremia in heart failure
Pathogenesis
Hyponatremia is a common electrolyte disorder in patients 
with decompensated HF (19 to 25%)4,5 and is frequently a 
complication of diuretic therapy.6 Its pathogenesis is multi-
factorial. Neurohormonal activation, in response to decreased 
cardiac output, plays an important role in the pathophysiology 
of HF and hyponatremia. One of the most important etiolo-
gies of hyponatremia in this setting is an inappropriate secre-
tion of AVP, making vasopressin receptors antagonism as a 
target for therapy for HF patients.7 The decrease of effective 
circulating volume and consequently the sympathetic nervous 
system (SNS) and RAAS activation lead to an increase in 
nonosmotically released AVP. The non-osmotic release of 
AVP might override the hypo-osmolality negative feedback 
on AVP production.8
Diuretic therapy induces hyponatremia because of the 
impairment of the kidney’s capability to reabsorb solute in the 
absence of water, the reduction of glomerular filtration rate 
due to volume depletion and the activation of the AVP system 
due to effective circulating volume decrease. Furthermore, 
the activation of the RAAS and SNS in response to diuretics 
contributes to the development of electrolyte disturbances 
and blunts the kidney response to diuretics in an effort to 
compensate for the changes in sodium and water balance.8
Vasopressin through stimulation of V1 and V2 recep-
tors aggravates the progression of HF, adversely affecting 
ventricular remodeling, worsening clinical congestion 
and contributing to hyponatremia. The V1a receptor is a G 
protein-coupled receptor which, when activated, increases 
intracellular calcium through the inositol-triphosphate 
pathway.9 Prolonged V1a receptor stimulation causes both 
arterial and venous constriction increasing myocardial pre-
load and afterload. Direct myocardial V1a receptor stimulation 
also contributes to left ventricular hypertrophy and adverse 
remodeling.
The V2 receptor, located in the renal collecting tubular 
cells, is linked to the adenylate cyclase signaling pathway, 
with intracellular cyclic adenosine monophosphate (cAMP) 
acting as the second messenger. V2 receptor mediates the 
ADH-induced stimulation of water permeability thereby per-
mitting osmotic equilibration with the renal interstitium.10 The 
inappropriate activation of the renal V2 receptors contributes 
to excessive water retention, volume expansion, increase of 
cardiac preload and dilutional hypo-osmolality with hypotonic 
hyponatremia. All these mechanisms perpetuate a vicious 
circle that can lead to disease progression and a worsening of 
the clinical status and prognosis of HF patients.11
Prognostic significance
Low serum sodium concentration in the setting of conges-
tion may be a marker of increased neurohormonal activation 
and greater severity of disease. The prognostic importance 
of hyponatremia in patients with severe chronic HF was 
first described by Lee and Packer.12 Five variables including 
serum sodium concentration, left ventricular stroke work 
index, serum creatinine concentration, serum bilirubin, 
and age were found to predict survival and pretreatment 
hyponatremia was the most powerful predictor of long term 
prognosis.
Several later studies demonstrated that hyponatremia at 
the time of admission is related to poor outcomes in patients 
hospitalized for acute heart failure syndrome (AHFS). A ran-
domized trial on 282 patients on the effect of nurse-directed, 
multidisciplinary intervention in comparison with usual care 
on 90-day readmission rates after AHFS hospitalization found 
that a decreasing plasma sodium level was one of the five 
independent predictors of readmission.13 Another study of 
4031 community-based patients hospitalized for worsening 
HF has shown that hyponatremia is one of the multivariable 
predictors of mortality at both 30 days and 1 year.1
Similar results emerged from retrospective analyses 
of several large randomized clinical trials. Investigators 
explored the relationship between admission serum sodium 
concentration and short term mortality in the OPTIME-CHF 
trial.14 There were 949 patients with AHFS randomized to 
receive 48 to 72 hours of intravenous milrinone or placebo 
in addition to standard therapy. In this study population, International Journal of Nephrology and Renovascular Disease 2010:3 53
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27% of patients were in the lowest sodium quartile (ie, serum 
sodium concentration 135 mEq/L). The number of hospi-
talization days for cardiovascular causes was 33% higher 
in this group and they also had a 2-fold higher in-hospital 
and 60-day mortality compared to those in the other plasma 
sodium quartiles. Similar results were also noted in another 
study among HF patients with preserved systolic function 
and hyponatremia.15
An analysis from the OPTIMIZE-HF registry of 
48,612 patients with AHFS showed a relationship between 
admission serum sodium concentration and clinical out-
comes.16 Hyponatremia was present in 20% of the OPTIMIZE-
HF cohorts with similar prevalence in patients with reduced or 
preserved ejection fraction. Lower admission serum sodium 
levels were associated with higher in-hospital mortality and 
longer mean hospital length of stay. In the follow up cohort, 
admission hyponatremia was associated with higher 60- to 
90-day mortality. Admission serum sodium concentration 
remained a significant independent predictor of outcomes after 
adjustment for other prognostic factors (Figure 1).
A post-hoc analysis of the ESCAPE trial evaluated 
the correlation of hyponatremia with hemodynamic status 
in patients hospitalized with severe HF.17 This study was 
designed to evaluate the utility of pulmonary artery catheter 
in 433 patients hospitalized with severe HF (NYHA IV and 
LVEF  30%). Patients were followed up for 180 days after 
discharge. Hyponatremia was initially present in 23.8% of 
study population and persisted during hospitalization in 
68.9% of these patients. After covariate adjustment, results 
confirmed that baseline serum sodium levels were an inde-
pendent predictor of 6 month mortality. Persistent hypona-
tremia was also associated with a significant increase of HF 
readmission rate as well as a composite endpoint of death and 
readmission rate. Moreover, the higher event rate associated 
with hyponatremic patients persists even after symptomatic 
and clinical improvement.
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Figure 1 Hyponatremia and prognosis in heart failure patients.
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AVP V2-receptor selective antagonist: 
tolvaptan
Mechanism of action, pharmacokinetic 
and pharmacodynamic profile
Tolvaptan, also known as OPC-41061, is an orally active 
nonpeptide AVP antagonist. It selectively blocks the binding 
of AVP to V2 receptor and inhibits the AVP-induced pro-
duction of cyclic AMP in human cells expressing V2 recep-
tors. V2 receptor antagonism promotes free water clearance 
(aquaresis), decrease in urine osmolality, and rise of serum 
sodium concentration without disturbing plasma potassium 
and magnesium levels. Tolvaptan metabolites have none 
or minimal activity for human V2 receptors compared with 
active drug.18
The pharmacokinetic, pharmacodynamic and drug 
interactions between tolvaptan and furosemide or hydro-
chlorothiazide (HCTZ) were studied in 12 healthy white 
men.19 In subjects receiving 60 mg of tolvaptan, the onset 
of the aquaretic and sodium increasing effects occurs within 
2 to 4 hours post-dose. A peak effect is observed between 
4 and 8 hours post-dose. Tolvaptan resulted in a greater 
24-hour urine volume/excretion rate than furosemide or 
HCTZ. However, concomitant administration of tolvaptan 
with furosemide or HCTZ resulted in a similar 24-hour 
urine volume/excretion rate compared with tolvaptan 
administration alone. In clinical studies on CHF patients, 
the addiction of tolvaptan to standard therapy, included 
furosemide, induced an increase in urine output compared 
to placebo plus diuretic. To confirm this possible synergic 
effect in HF patients, studies comparing tolvaptan alone 
versus tolvaptan plus diuretic effects are necessary.
Tolvaptan is metabolized by CYP3A system and concom-
itant use of strong CYP3A inhibitors such as clarithromycin 
or ketoconazole is cautioned.20 Tolvaptan administration 
does not affect steady-state amiodarone concentration, an 
antiarrhythmic drug commonly prescribed for patients with 
congestive heart failure and a known inhibitor of other drugs 
metabolized by CYP3A4. Potent CYP3A inducers such as 
rifampicin reduced tolvaptan plasma concentrations by 85%. 
Tolvaptan is also a substrate for P-glycoprotein and admin-
istration with P-glycoprotein inhibitors such as cyclosporine 
requires a dose reduction.21
Treatment with tolvaptan is associated with a reduc-
tion of the extracellular fluid volume which could result in 
increased serum potassium. Serum potassium levels should 
be monitored after initiation of tolvaptan treatment in patients 
with a serum potassium 5 mEq/L and in those who are 
receiving drugs known to increase serum potassium levels. 
Although specific interaction studies were not performed 
in CHF clinical studies tolvaptan was used concomitantly 
with standard therapy (including beta-blockers, angiotensin 
receptor blockers, angiotensin converting enzyme inhibi-
tors and potassium sparing diuretics) and plasma potassium 
concentrations are not significantly changed.
Tolvaptan in experimental studies, human 
studies and clinical trials
Preclinical studies, conducted on animals and in healthy 
subjects, showed that V2 receptor antagonist administration 
produced aquaretic effect (increase in free water excre-
tion) without sodium loss, without activation of the RAAS 
and changes of renal function.22,23 These favorable results 
appeared to be consistent among several clinical trials on 
HF patients (Table 1).
Gheorghiade et al was the first to conduct a double-
blind, randomized trial to evaluate the ability of tolvaptan 
to remove excess fluid when added to a diuretic therapy in 
patients with symptomatic chronic HF.24 In this study, 254 
outpatients with NYHA 2 or 3 HF were randomly assigned to 
receive placebo or one of three doses of tolvaptan (30, 45, or 
60 mg/day) for 25 days in addition to standard therapy. The 
tolvaptan group demonstrated a significant decrease in body 
weight at day 1 that was maintained throughout the 25 days. 
Moreover, there was a significant improvement of clinical 
signs and symptoms observed. There was also an increase 
in urine output with significantly lower urine osmolality and 
urinary sodium concentration compared to placebo group. 
More hyponatremic patients in the tolvaptan group (80% vs 
40% in placebo) had normalization in serum sodium levels. 
The increase in serum sodium starts at day 1 and maintained 
throughout the study. There were no changes in renal function 
or blood pressure.
The Acute and Chronic Therapeutic Impact of Vasopres-
sin antagonist in congestive HF (ACTIV in CHF prospective 
trial) evaluated the clinical effects of tolvaptan in 319 patients 
hospitalized with worsening heart failure. All doses (30, 60, 
90 mg/day) of tolvaptan resulted in significant body weight 
reduction over placebo.25 Tolvaptan also improved serum 
sodium levels in patients with hyponatremia. There were 
no differences in worsening heart failure at 60 days between 
the tolvaptan and placebo groups (P = 0.88). However, while 
bodyweight declined on tolvaptan, there were no statistically 
significant differences in the signs and symptoms of clinical 
congestion, except for dyspnea (P = 0.04). Of note, patients 
randomized to tolvaptan used less furosemide and maintained International Journal of Nephrology and Renovascular Disease 2010:3 55
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a lower body weight, without differences in heart rate, blood 
pressure, potassium level or renal function. Retrospective 
analyses showed that patients with hyponatremia (21.3%) had 
a threefold increase in 60-day mortality compared with nor-
monatremic patients and the improvement in hyponatremia 
during hospitalization, even if modest, was associated with 
improved outcomes.26 Particularly a lower 60-day mortality 
in all tolvaptan groups compared to placebo group (P  0.05) 
among patients with severe congestion and elevated blood 
urea nitrogen levels at baseline was detected.27
The Study of Ascending Levels of Tolvaptan in hypona-
tremia 1 and 2 (SALT-1 and SALT-2) evaluated the effect of 
tolvaptan in patients with either euvolemic or hypervolemic 
hyponatremia due to SIADH, chronic HF or cirrhosis.28 
Tolvaptan was started at 15 mg/day, increased to 30 mg/day 
and then to 60 mg/day, if necessary, based on serum sodium 
concentration. Tolvaptan was more effective than placebo in 
increasing the average daily area under the curve for serum 
sodium concentrations during the first 4 days and after the 
full 30 days of therapy. Within 8 hours of the first administra-
tion of tolvaptan (first observation point), the serum sodium 
concentration was significantly higher in the tolvaptan group 
for both the total population and the subgroups stratified 
according to the degree of hyponatremia.
A multicenter, double-blind, placebo-controlled study, 
demonstrated that long term (1 year) administration of the 
tolvaptan (30 mg/day), have no significant effect on reduc-
ing left ventricular end-diastolic and end-systolic volume 
in 120 patients with stable CHF (NYHA II/III).29 In this 
study there were no significant differences in serum sodium 
or potassium between groups across the year of therapy. 
A post hoc analysis showed a significant reduction in mor-
tality and worsening HF over 1 year in patients treated with 
tolvaptan in comparison with placebo group (P = 0.027). 
Table 1 Tolvaptan clinical trials in heart failure
Study No. of patients and 
characteristics
Dosage Primary endpoint Results and comments Adverse 
effects
Gheorghiade 
et al24
N = 254 
Pts with CHF in 
outpatient setting 
(NYHA class I–IV) 
and volume overload
Tolvaptan  
(30, 45 or  
60 mg/day) for  
25 days vs placebo
Decrease in body weight Significant decrease in body weight 
in all tolvaptan groups at 24 h, with 
a concomitant increase in urine 
volume, lower urine osmolality and 
urinary sodium concentration
Dry mouth, 
thirst and 
polyuria
ACTIv in 
CHF25
N = 319 
Pts with eF  40% 
hospitalized for 
congestive HF
Tolvaptan  
(30, 60 or  
90 mg/day) for 
up to 60 days vs 
placebo
1)   In hospital end-point: change 
in body weight at 24 hrs 
2)   Outpatient end-point:  
worsening heart failure at  
60 days after randomization
Dose independent decrease  
in body weight at 24 h in tolvaptan 
group 
No differences in worsening HF  
at 60 days
Thirst and dry 
mouth, dizzi-
ness, nausea, 
hypotension
SALT-1 and 
SALT-228
N1 = 205 N2 = 243 
CHF and other 
hospitalized pts 
with euvolemic or 
hypervolemic  
hyponatremia
Tolvaptan  
(15–60 mg/day) 
for 30 days vs 
placebo
Change in serum sodium concen-
trations (from baseline to 4th and 
to 30th day)
Serum sodium concentrations 
Increased significantly more with 
tolvaptan during the first 4 days  
(P  0.001) and after the full  
30 days of therapy (P  0.001)
Thirst and dry 
mouth, urinary 
frequency
Udelson29 N = 240 
Pts with HF  
(NYHA class II/III) 
and eF  30%
Tolvaptan  
(30 mg/day) for  
1 year vs placebo
To evaluate the effect of long-term 
administration of tolvaptan on left 
ventricular remodeling
There was no difference on Lv  
volumes 
*post hoc analysis: improvement 
survival in tolvaptan group
Urinary fre-
quency, thirst 
and dry mouth
eveReST 
Clinical  
Status Trial31
N = 4133 
Pts with eF  40%, 
NYHA class III/Iv, 
hospitalized for  
worsening CHF
Tolvaptan  
(30 mg/day) for a 
minimum of  
60 days vs placebo
1) Change in global clinical status
2)   Change in body weight at  
7 days or at discharge
Oral tolvaptan in addition to 
standard therapy improved many, 
though not all, heart failure signs 
and symptoms, without serious 
adverse events
Thirst and dry 
mouth
eveReST Out-
come Trial32
N = 4133 
Pts with eF  40%, 
NYHA class III/Iv, 
hospitalized for  
worsening CHF
Tolvaptan  
(30 mg/day) for  
a minimum of  
60 days vs placebo
1) All-cause mortality 
2)   Composite of cardiovascular 
death or hospitalization  
for HF
No effect (either favorable  
or unfavorable) of long term 
tolvaptan treatment
Thirst and dry 
mouth
Abbreviations: CHF, chronic heart failure; eF, ejection fraction; HF, heart failure; Lv, left ventricular; NHYA, New York Heart Association.International Journal of Nephrology and Renovascular Disease 2010:3 56
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These outcome findings were hypothesis generating of 
EVEREST program.
The EVEREST trial is a program of pivotal trials designed 
to investigate the effect of tolvaptan administration (30 mg/day) 
in addition to standard therapy in 4133 patients hospitalized 
for AHFS with signs and symptoms of volume overload. 
EVEREST consisted of three studies: 2 identical studies 
(A and B) designed to investigate short-term effects on clini-
cal status and symptoms and an outcome study consisting 
of all randomized patients designed primarily to investigate 
long-term clinical outcomes of all cause mortality and com-
bined cardiovascular mortality or HF readmissions.30 The 
median follow-up period was 9.9 months. The short-term 
trials demonstrated a significant improvement in primary 
composite clinical end point (patient-assessed global clinical 
features and body weight loss at 7 day or discharge if earlier), 
and in secondary clinical end points (bodyweight loss at day 1 
and day 7, patient-assessed dyspnea at day1, edema score at 
day 7) in patients treated with tolvaptan.31
Among patients with baseline serum sodium levels 
134 mEq/L (8% of total), the mean serum sodium 
concentration significantly increased in the tolvaptan group 
compared to placebo group. This effect was observed since 
day 1 and persisted throughout the follow-up period (Figure 2). 
In spite of the significant improvement in short-term clinical 
status outcomes and in increasing sodium serum concentration 
among hyponatremic patients, tolvaptan administration in 
addition to standard therapy did not affect long term mortality 
or heart failure-related morbidity.32 However dose titration 
of treatment considering clinical status (entity of dyspnea, 
peripheral edema, pulmonary congestion, body weight) and 
a dose adjustment based on clinical response could lead to 
better results in term of symptoms and outcomes.
Further prospective studies in a selected congestive HF 
population with hyponatremia, using clinical-status titrated 
dose of tolvaptan, are needed to determine whether serum 
sodium normalization will be translated into a better long-term 
prognosis.
Safety and tolerability
Symptomatic hyponatremia are true emergencies that 
demand prompt and definitive intervention. An important 
consideration in the treatment of hyponatremia is the rate at 
which serum sodium is corrected. Overly rapid correction 
of chronic hyponatremia leads to pontine and extrapontine 
myelinolysis that causes irreversible neurologic deficits. 
The challenge in treating severe hyponatremia is finding 
the right balance so as not to risk progression to cerebral 
edema from undercorrection of hyponatremia and avoid the 
osmotic demyelination syndrome from overcorrection of this 
electrolyte disorder.
Among patients with acute hyponatremia, defined as 
development of hyponatremia within 48 hours, the risk of 
persistent marked hyponatremia far exceeds any risk from 
correction of serum sodium and should not deter aggressive 
treatment. Patients seem to tolerate rates of correction that 
would be harmful for chronic hyponatremia (48 hours).33 
There have been no reports of osmotic demyelination syn-
drome or related neurologic sequelae to date among patients 
who took or who are currently taking tolvaptan.
The data from clinical studies on short and long-term 
outcomes confirmed an overall safety profile of tolvaptan in a 
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very large population of patients with HF and hyponatremia. 
In the EVEREST program the benefits on short term outcomes 
(consistent increases in urine output, a reduction in body 
weight, and an improvement in many signs and symptoms) 
have been seen without unfavorable changes in blood pressure, 
heart rate, electrolytes, or renal function. The neutral long-term 
outcome effects, different from other treatments in AHFS, 
confirm the safety of tolvaptan chronically administered.
The most common adverse effects (incidence 5% than 
placebo) to tolvaptan reported in clinical trials were thirst, dry 
mouth, polyuria and urinary frequency, which are consistent 
with the pharmacologic action of the drug. Other side effects 
reported, but not statistically significant in comparison with 
placebo (standard therapy), includes dehydration with hypo-
tension, acute renal failure and hyperglycemia. Tolvaptan 
should not be used in hypovolemic hyponatremia or in patients 
with glomerular filtration rate less than 10 mL/min/1.73 m², 
such as those with end stage renal disease with dilutional 
hyponatremia.34
Implication for therapy
Conventional treatment of hyponatremia in HF patients 
is based largely on the restriction of fluid intake, saline 
and diuretic administration, but often these therapeutic 
approaches are ineffective.35,36 Hyponatremia in HF is 
frequently associated with reduced diuretic efficacy due to 
diminished distal tubular sodium delivery and secondary 
hyperaldosteronism. This could be particularly problematic 
when patients are not compliant with restrictions in free 
water intake.37
A combination of hypertonic saline solution (HSS) and 
loop diuretics is often added to fluid restriction, but this 
more aggressive treatment is usually advocated for patients 
with severe hyponatremia who have profound neurological 
symptoms.38 Licata et al studied the effects of high-dose 
furosemide and small-volume HSS infusion (group 1) in 
comparison with a high dose of furosemide as bolus (group 2) 
in 107 patients with refractory CHF who were unresponsive 
to high oral doses of furosemide.39 A significant increase in 
daily diuresis and natriuresis was observed in both groups, 
but it was more significant in the group receiving HSS 
(P  0.05). The serum sodium level increased in group 1 
and decreased in group 2 (P  0.05). HSS administration 
was well tolerated. It also improved the quality of life and 
potentiates the diuretic action of furosemide, overcoming 
established resistance to loop diuretics.
The V2 receptor antagonists may be viewed as the new class 
of agents for removing excess body water. These “aquaretic” 
agents have many favorable properties in comparison with 
loop diuretic.9,11,39,40 One in particular is its property to improve 
serum sodium concentrations and increase plasma osmolality 
without depletion of potassium, changes in blood pressure, 
renal function or neurohormonal activation. In comparison 
with furosemide, tolvaptan increased urine output without a 
decrease in renal blood flow and glomerular filtration rate.40
Gheorghiade et al randomized tolvaptan alone versus 
fluid restriction plus placebo in 28 hospitalized patients with 
serum sodium concentration 135 mEq/L. Tolvaptan was 
started at 10 mg/day and titrated to 60 mg/day. Active treat-
ment was continued for up to 27 days, with a follow-up until 
65th day. Normalization of serum sodium (primary endpoint) 
occurred in 50% of patients by day 4 when treated with 
tolvaptan and by day 8 on fluid restriction (P  0.03) with a 
significant greater increase of serum sodium concentration 
in the tolvaptan group compared to the fluid restriction group 
at their last inpatient visit.41
The Food and Drug Administration (FDA) has approved 
the use of tolvaptan for the treatment of clinically significant 
hypervolemic and euvolemic hyponatremia (serum sodium 
concentration 125 mEq/L or less marked hyponatremia 
that is symptomatic and has resisted correction), including 
patients with HF, cirrhosis and SIADH.42
Other vasopressin receptor 
antagonist
Lixivaptan (VPA-985) is another oral V2-receptor selective 
antagonist. In a multicenter, randomized, placebo-controlled 
trial,43 lixivaptan appeared to be effective and safe in treat-
ment of water retention and dilutional hyponatremia such as 
SIADH, HF and liver cirrhosis. Abraham et al investigated 
in a randomized, double-blind, placebo-controlled study 
the aquaretic response to increasing doses (10 to 400 mg 
single dose) of lixivaptan in 42 diuretic-requiring patients 
with mild-to-moderate CHF.44 This study demonstrated 
a dose-dependent increase in solute-free water excretion 
and improvement in serum sodium concentration after V2 
receptor antagonist treatment. Higher doses of lixivaptan 
may produce significant dehydration and will require close 
monitoring with their use.
At present, no long-term outcome data are available. 
The ongoing BALANCE study, a multicenter, random-
ized, double-blind placebo controlled trial designed to test 
the effects of titrated dose of lixivaptan administered for 
60 days, on short- and long-term outcomes in hyponatremic 
patients with advanced HF. The primary end point of the International Journal of Nephrology and Renovascular Disease 2010:3 58
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study is the efficacy and safety of lixivaptan in normalizing 
serum sodium levels and reducing congestion in HF patients 
with hyponatremia. Secondary end point includes all cause 
mortality, HF hospitalization, cardiovascular effects and 
weight loss.45
Conivaptan is the only intravenous combined V1a/V2 
receptor antagonist that has been evaluated in humans 
and is FDA-approved for the treatment of euvolemic and 
hypervolemic hyponatremia.42 Experimental studies showed 
that conivaptan has a good pharmacological profile46 and 
is a potent inhibitor of AVP-induced protein synthesis of 
cardiomyocytes. It may have beneficial effects in the devel-
opment and regression of cardiomyocyte hypertrophy.47 
Combined V1a/V2 receptor antagonists might be useful in 
diseases associated with a combination of increased periph-
eral resistance and dilutional hyponatremia.
Human studies in patients with stable advanced chronic 
HF showed that conivaptan induces a dose-dependent increase 
in urine output, decrease of pulmonary capillary wedge pres-
sure, right atrial pressure48 and improvement in serum sodium 
concentration.49 Current plans for conivaptan are focused on 
treatment for AHFS. Recently, Goldsmith et al performed a 
pilot study to evaluate the efficacy and safety of intravenous 
conivaptan in treating AHFS.50 The results of this study showed 
that conivaptan increases urine output significantly more than 
placebo. Conivaptan was well tolerated with no evidence of 
worsening HF. Further studies are still needed to determine the 
role of this drug in treatment of AHFS and hyponatremia.
Tolvaptan in other hyponatremic 
settings
Although the clinical manifestations are different for SIADH, 
liver cirrhosis, and HF, they share the same pathophysiologic 
mechanism responsible for persistent hyponatremia – 
nonosmotically stimulated AVP release. The efficacy of tolvap-
tan in improving euvolemic and hypervolemic hyponatremia due 
to SIADH or liver cirrhosis was tested in two trials previously 
mentioned. Excluding hypothyroidism, adrenal insufficiency, 
advanced renal disease (creatinine  3.5 mg/dL), Child–Pugh 
score  10, serum sodium concentration  120 mEq/L with 
neurologic impairment, and systolic hypotension, the SALT-1 
and SALT-2 trials found that tolvaptan was effective in increas-
ing serum sodium concentration at day 4 and day 30 also in 
these hyponatremic settings. The improvement in serum sodium 
concentration also significantly improved the scores for the 
Mental Component Summary (for vitality, social functioning, 
emotionally limited accomplishment, calmness, and sadness) 
of the SF 12 Health survey.28
Another potential clinical application of vasopressin 
receptor antagonists that is under investigation is its use in 
autosomal-dominant polycystic kidney disease (ADPKD). 
There are currently no good treatment options to retard 
progression of this condition and most patients require renal 
replacement therapy and/or renal transplantation. The mor-
bidity and mortality associated with ADPKD is substantial. 
The vasopressin V2 receptors have been implicated in cyst 
formation and enlargement in polycystic kidney disease. The 
long-term safety and efficacy of tolvaptan in retarding (rate 
of renal volume change) progression of ADPKD is currently 
being studied.51
Conclusion
Hyponatremia in HF is not just a mere inconvenience. It 
is an independent predictor of adverse outcomes including 
longer hospital stay, higher readmission rates, and increased 
short- and long-term mortality. The use of tolvaptan has been 
shown to induce a rapid and sustained aquaretic response 
useful for treatment of hyponatremia in patients with acute 
and chronic HF. Tolvaptan improves short-term outcomes 
and is proven to be safe in the treatment of AHFS, especially 
in hyponatremic settings. Further prospective studies of the 
vaptans, using titrated doses based on serum sodium and 
clinical status, are necessary to determine whether serum 
sodium normalization will be translated into a better long-
term prognosis in selected hyponatremic patients with HF.
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